Genscript Biotech Management

Management Kriterienprüfungen 2/4

Genscript Biotech CEO ist Sherry Shao , ernannt in Jul 2021, hat eine Amtszeit von 3.83 Jahren. Die jährliche Gesamtvergütung beträgt $3.62M , bestehend aus 9.7% Gehalt und 90.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.036% der Aktien des Unternehmens, im Wert von HK$8.73M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.1 Jahre bzw. 4.5 Jahre.

Wichtige Informationen

Sherry Shao

Geschäftsführender

US$3.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	9.7%
Amtszeit als Geschäftsführer	3.8yrs
Eigentum des Geschäftsführers	0.04%
Durchschnittliche Amtszeit des Managements	4.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.5yrs

Jüngste Management Updates

Recent updates

Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Apr 07

Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump

Feb 12

Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 20

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Nov 19

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Oct 01

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Sep 16

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Aug 02

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Jun 05

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

May 10

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 13

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Mar 13

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 26

Is Genscript Biotech (HKG:1548) A Risky Investment?

Nov 21

Is Genscript Biotech (HKG:1548) A Risky Investment?

Aug 22

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Apr 04

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 02

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Feb 07

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Dec 14

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 09

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Sherry Shao im Vergleich zu den Einnahmen von Genscript Biotech verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Dec 31 2024	US$4m	US$352k	-US$67m
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$136m
Dec 31 2023	US$2m	US$353k	US$423m

Vergütung im Vergleich zum Markt: SherryDie Gesamtvergütung ($USD3.62M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD548.72K).

Entschädigung vs. Einkommen: SherryDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Sherry Shao (43 yo)

3.8yrs

Amtszeit

US$3,615,000

Vergütung

Ms. Weihui Shao, also known as Sherry, is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined t...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jiange Meng	Executive Chairman	9.8yrs	US$531.00k	0.015% HK$ 3.6m
Weihui Shao	CEO & COO	3.8yrs	US$3.62m	0.036% HK$ 8.7m
Ye Wang	Co-Founder	23.3yrs	US$914.00k	0.037% HK$ 9.0m
Luquan Wang	Co-Founder & Non-Executive Director	no data	keine Daten	0.029% HK$ 7.1m
Fangliang Zhang	Co-Founder & Executive Director	2.4yrs	US$611.00k	keine Daten
Li Zhu	Chief Strategy Officer & Executive Director	4.5yrs	US$384.00k	0.050% HK$ 12.0m
Shiniu Wei	Chief Financial Officer	4.4yrs	keine Daten	keine Daten
Kening Li	General Counsel & Chief Compliance Officer	no data	keine Daten	keine Daten
Raymond Miller	Head of Corporate Communications	no data	keine Daten	keine Daten
Aylin Bilgin	Chief Marketing Officer for GenScript Life Science Group	less than a year	keine Daten	keine Daten
Bhama Parimoo	Head of Global Diversity	no data	keine Daten	keine Daten
Ernest Lee	Head of Sustainability	no data	keine Daten	keine Daten

4.1yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: 1548Das Führungsteam des Unternehmens gilt als erfahren (4.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jiange Meng	Executive Chairman	9.8yrs	US$531.00k	0.015% HK$ 3.6m
Ye Wang	Co-Founder	10yrs	US$914.00k	0.037% HK$ 9.0m
Luquan Wang	Co-Founder & Non-Executive Director	10yrs	keine Daten	0.029% HK$ 7.1m
Fangliang Zhang	Co-Founder & Executive Director	3yrs	US$611.00k	keine Daten
Li Zhu	Chief Strategy Officer & Executive Director	4.5yrs	US$384.00k	0.050% HK$ 12.0m
Carl June	Member of Advisory Board	1.3yrs	keine Daten	keine Daten
George Church	Member of Advisory Board	5.7yrs	keine Daten	keine Daten
David Liu	Member of Scientific Advisory Board	1.2yrs	keine Daten	keine Daten
Zumian Dai	Independent Non-Executive Director	no data	US$179.00k	0.0017% HK$ 409.8k
Jiuan Pan	Independent Non-Executive Director	6.5yrs	US$86.00k	0.00044% HK$ 106.7k
Yiu Leung Cheung	Independent Non-Executive Director	1.1yrs	US$60.00k	keine Daten
Chenyang Shi	Independent Non-Executive Director	1.1yrs	US$60.00k	keine Daten

4.5yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrener Vorstand: 1548Die Vorstandsmitglieder gelten als erfahren (4.5 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/05/03 21:48
Aktienkurs zum Tagesende	2025/05/02 00:00
Gewinne	2024/12/31
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Genscript Biotech Corporation wird von 15 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Jin Zhang	China International Capital Corporation Limited
Yue-Kwong Lui	China Renaissance Securities
Shitong Han	Citic Securities Co., Ltd.

Genscript Biotech Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Co-Founder exercised options and sold HK$39m worth of stock

Co-Founder exercised options and sold HK$52m worth of stock

Board Member recently sold HK$481k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 29, 2025

Genscript Biotech Corporation Announces Establishment of A Sub-Committee of the Risk Management and ESG Committee

Executive Chairman exercised options and sold HK$5.5m worth of stock

Recent updates

Co-Founder exercised options and sold HK$39m worth of stock

Co-Founder exercised options and sold HK$52m worth of stock

Board Member recently sold HK$481k worth of stock

Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation, Annual General Meeting, May 29, 2025

Genscript Biotech Corporation to Report Fiscal Year 2024 Results on Mar 11, 2025

Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump

Genscript Biotech Corporation Announces Establishment of A Sub-Committee of the Risk Management and ESG Committee

Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate

Executive Chairman exercised options and sold HK$5.5m worth of stock

Executive Chairman recently sold HK$396k worth of stock

Co-Founder exercised options and sold HK$53m worth of stock

Co-Founder exercised options and sold HK$43m worth of stock

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Now 22% overvalued after recent price rise

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Genscript Biotech Corporation Announces Board Appointments

Consensus EPS estimates fall by 46%

First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Independent Non-Executive Director exercised options and sold HK$1.6m worth of stock

Non-Executive Director exercised options and sold HK$2.4m worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

Is Genscript Biotech (HKG:1548) A Risky Investment?

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Consensus revenue estimates fall by 19%

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Is Genscript Biotech (HKG:1548) A Risky Investment?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Now 24% undervalued

Now 20% undervalued

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Less than half of directors are independent

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Is Genscript Biotech (HKG:1548) Using Debt Sensibly?